Fibromyalgia

Disease-a-Month

Volumn 61, Issue 3, 2015, Pages 66-111

  Jay, Gary W ^a   Barkin, Robert L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BACLOFEN; CALCITONIN; CHLORPROMAZINE; CLONAZEPAM; CYCLOBENZAPRINE; DOPAMINE RECEPTOR STIMULATING AGENT; METAXALONE; MIRTAZAPINE; MU OPIATE RECEPTOR; OLANZAPINE; ONDANSETRON; ORPHENADRINE; PRASTERONE; RIBOSE; S ADENOSYLMETHIONINE; SEROTONIN UPTAKE INHIBITOR; TEMAZEPAM; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TROPISETRON; TRYPTOPHAN; UNINDEXED DRUG; VENLAFAXINE; ZOLPIDEM; ZOPICLONE;

ACUPUNCTURE; ALTERNATIVE MEDICINE; ANALGESIA; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL SENSITIVITY SYNDROME; CHIROPRACTIC; COGNITIVE DEFECT; COGNITIVE THERAPY; COMORBIDITY; DYSAUTONOMIA; FATIGUE; FIBROMYALGIA; GRAY MATTER; HUMAN; INSULA; KINESIOTHERAPY; MEDICATION THERAPY MANAGEMENT; MYOFASCIAL PAIN; NONHUMAN; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PHYSIOTHERAPY; RELAXATION TRAINING; RESTLESS LEGS SYNDROME; REVIEW; SENSITIZATION; SYMPTOM; DIFFERENTIAL DIAGNOSIS; DISEASE MANAGEMENT; PRACTICE GUIDELINE; PSYCHOLOGY;

DIAGNOSIS, DIFFERENTIAL; DISEASE MANAGEMENT; FIBROMYALGIA; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84924529920     PISSN: 00115029     EISSN: 15578194     Source Type: Journal    
DOI: 10.1016/j.disamonth.2015.01.002     Document Type: Review

References (445)

1. Reynolds M.D. The development of the concept of fibrositis. J Hist Med Allied Sci 1983, 38:5-35.
2. Simons D.G. Muscle pain syndrome-part 1. Am J Phys Med 1975, 54:289-311.
3. Gowers W.R. Lumbago: its lessons and analogues. Br Med J 1904, 1:117-121.
4. Traut E.F. Fibrositis. J Am Geriatr Soc 1968, 16:531-538.
5. Yunus M.B., Masi A.T., Calabro J.J., et al. Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Semin Arthritis Rheum 1981, 11:151-171.
6. Wolfe F., Smythe H.A., Yunus M.B., et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990, 33:160-172.
7. Goldenberg D.L. Fibromyalgia syndrome: an emerging but controversial condition. J Am Med Assoc 1987, 257:2782-2787.
8. Bengtsson A., Henriksson K.G., Jorfeldt L., et al. Primary fibromyalgia. A clinical and laboratory study of 55 patients. Scand J Rheumatol 1986, 40:340-347.
9. Wolfe F., Ross K., Anderson J., et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995, 38:19-28.
10. Yunus M.B., Inanici F. Fibromyalgia syndrome: clinical features, diagnosis and biopathophysiologic mechanisms. Myofascial Pain and Fibromyalgia: Trigger Point Management 2002, 3-31. Mosby, St. Louis, MO. 2nd ed. E.S. Rachlin, I.S. Rachlin (Eds.).
11. Wolfe F. The fibromyalgia problem. J Rheumatol 1997, 24:1247-1249.
12. Barsky A.J., Borus J.F. Functional somatic syndromes. Ann Intern Med 1999, 130:910-921.
13. Hadler N.M. Fibromyalgia: La maladie est morte. Vive le malade!. J Rheumatol 1997, 24:1250-1251.
14. Lawrence R.C., Hochberg M.C., Kelsey J.L., et al. Estimates of prevalence of selected arthritic and musculoskeletal diseases in the United States. J Rheumatol 1989, 16:427-441.
15. Magni G., Marchetti M., Moreschi C., et al. Chronic musculoskeletal pain and depressive symptoms in the National Health and Nutrition Examination. I. Epidemiologic follow-up study. Pain 1993, 53:163-168.
16. White K.P., Harth M. The occurrence and impact of generalized pain. Baillieres Clin Rheumatol 1999, 13:379-389.
17. White K.P., Speechley M., Harth M., et al. Comparing self-reported function and work disability in 100 random community cases of fibromyalgia versus control in London, Ontario: The London Fibromyalgia Epidemiology Study. Arthritis Rheum 1999, 42:76-83.
18. White D.P., Speechley M., Harth M., et al. The London Fibromyalgia Epidemiology Study: comparing the demographic and clinical characteristics in 100 random community cases of fibromyalgia versus controls. J Rheumatol 1999, 26:1577-1585.
19. White K.P., Harth M., Speechley M., et al. A general population study of fibromyalgia tender points in non-institutionalized adults with chronic widespread pain. J Rheumatol 2000, 27:2677-2682.
20. White D.P., Harth M. Classification, epidemiology and natural history of fibromyalgia. Curr Pain Headache Rep 2001, 5:320-329.
21. Roizenblatt S., Tufik S., Goldenberg J., et al. Juvenile fibromyalgia: clinical and polysomnographic aspects. J Rheumatol 1997, 24:579-585.
22. Yunus M.B., Masi A.T. Juvenile primary fibromyalgia syndrome. Arthritis Rheum 1985, 28:138-144.
23. Yunus M.B., Holt G.S., Masi A.T., et al. Fibromyalgia syndrome among the elderly: comparison with younger patients. J Am Geriatr Soc 1988, 35:987-995.
24. Porter-Moffitt S., Gatchel R.J., Robinson R.C., et al. Biopsychosocial profiles of different pain diagnostic groups. J Pain 2006, 7(5):308-318.
25. White K.P., Speechley M., Harth M., et al. The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol 1999, 26:1570-1576.
26. McNally J.D., Matheson D.A., Bakowsky V.S. The epidemiology of self-reported fibromyalgia in Canada. Chronic Dis Can 2006, 27(1):9-16.
27. Weir P.T., Harlan G.A., Nkoy F.L., et al. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes. J Clin Rheumatol 2006, 12(3):124-128.
28. Ifergane G., Buskila D., Simiseshvely N., et al. Prevalence of fibromyalgia syndrome in migraine patients. Cephalalgia 2006, 26(4):451-456.
29. Jay G.W. Chronic Pain 2007, 91-106. Informa Healthcare, New York.
30. Burgmer M., Pogatzki-Zahn E., Gaubitz M., Wessoleck E., Heuft G., Pfeiderer B. Altered brain activity during pain processing in fibromyalgia. Neuroimage 2009, 44(2):502-508.
31. Gracely R.H., Petzke F., Wolf J.M., Clauw D.J. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 2002, 46(5):1333-1343.
32. Yunus M.B. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin Arthritis Rheum 2007, 36(6):339-356.
33. Bennett R.M. Fibromyalgia and the disability dilemma. A new era in understanding a complex, multidimensional pain syndrome. Arthritis Rheum 1996, 39(10):1627-1634.
34. Reilly P.A., Littlejohn G.O. Peripheral arthralgic presentation of fibrositis/fibromyalgia syndrome. J Rheumatol 1992, 19:281-283.
35. Zoppi M., Maresca M. Symptoms accompanying fibromyalgia. Reumatismo 2008, 60(3):217-220.
36. McCain G.A. Fibromyalgia and myofascial pain. Textbook of Pain 1994, 475-493. Churchill Livingstone, Edinburgh, UK. 3rd ed. P.D. Wall, R. Melzack (Eds.).
37. Yunus M.B., Inanici F., Aldag J.C., et al. Fibromyalgia in men: comparison of clinical features with women. J Rheumatol 2000, 27:485-490.
38. Moldofsky H. Chronobiological influences on fibromyalgia syndrome: theoretical and therapeutic implications. Baillieres Clin Rheumatol 1994, 8:801-810.
39. Wolfe F., Clauw D.J., Fitzcharles M.A., et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol 2011, 38(6):1113-1122.
40. Wolfe F., Clauw D.J., Fitzcharles M.A., et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010, 62(5):600-610.
41. Bennett R., Friend R., Marcus D., et al. Criteria for the diagnosis of fibromyalgia: validation of the modified 2010 preliminary ACR criteria and the development of alternative criteria. Arthritis Care Res 2014; 4, [Epub ahead of print].
42. Fibromyalgia Network. New clinical fibromyalgia diagnostic criteria. Accessed 11.05.14. http://www.fmnetnews.com.
43. Behm FG, Gavid IM, Karpenko O, et al. Unique immunological patterns in fibromyalgia. BMC Clinical Pathology. 2012 Accessed 13.07.14. http://www.biomedcentral.com/1472-6890/12/25.
44. Quintner J. Fact or fiction: a blood test for fibromyalgia? Arthritis Foundation of WA. 2014 Accessed 13.07.14. http://www.arthritiswa.org.au/news/view/fact-or-fiction-the-fm-test.html.
45. Tunks E., McCain G.A., Hart L.E., et al. The reliability of examination for tenderness in patients with myofascial pain, chronic fibromyalgia and controls. J Rheumatol 1995, 22:944-952.
46. Russell I.J., Vipraio G.A., Morgan W.W., et al. Is there a metabolic basis for the fibrositis syndrome?. Am J Med 1986, 81:50-56.
47. Yunus M.B. Gender differences in fibromyalgia and other related syndromes. J Gend Specif Med 2002, 5(2):42-47.
48. Wigers S.H. Fibromyalgia-an update. Tidsskr Nor Laegeforen 2002, 122:1300-1304.
49. Celentano J., Palmaricciotti V., Nyssen AS., et al. Fibromyalgie et lombalgie chronique: étude des facteurs invalidants et facteurs facilitateurs à la réinsertion et au maintien professionnel. Douleur et Analgésie 2011, 24(1):46-49.
50. Jay G.W. Fibromyalgia. Practical Guide To Chronic Pain Syndromes. 2010, 144-180. Informa Healthcare, New York. G.W. Jay (Ed.).
51. Smitherman S.R. Peripheral and central sensitization in fibromyalgia: pathogenetic role. Curr Pain Headache Rep 2002, 6(4):259-266.
52. Staud R. Evidence of involvement of central neural mechanisms in generating fibromyalgia pain. Curr Rheumatol Rep 2002, 4(4):299-305.
53. Clauw D.J. Fibromyalgia: more than just a musculoskeletal disease. Am Fam Physician 1995, 52(3):843-851. 853-854.
54. Staud R., Spaeth M. Psychophysical and neurochemical abnormalities of pain processing in fibromyalgia. CNS Spectr 2008, 13(3 suppl 5):12-17.
55. Malt E.A., Olafsson S., Lund A., et al. Factors explaining variance in perceived pain in women with fibromyalgia. BMC Musculoskelet Disord 2002, 3:12-16.
56. Staud R., Domingo M. Evidence for abnormal pain processing in fibromyalgia syndrome. Pain Med 2001, 2(3):208-215.
57. Hurtig I.M., Raak R.I., Kendall S.A., et al. Quantitative sensory testing in fibromyalgia patients and in healthy subjects: identification of subgroups. Clin J Pain 2001, 17(4):316-322.
58. Granot M., Buskila D., Granovsky Y., et al. Simultaneous recording of late and ultra-late pain evoked potentials in fibromyalgia. Clin Neurophys 2001, 112(10):1881-1887.
59. Montoya P., Sitges C., Garcia-Herrera M., et al. Reduced brain habituation to somatosensory stimulation in patients with fibromyalgia. Arthritis Rheum 2006, 54(6):1995-2003.
60. Martinez-Lavin M., Hermosillo A.G., Mendoza C., et al. Orthostatic sympathetic derangement in subjects with fibromyalgia. J Rheumatol 1997, 24(4):714-718.
61. Martinez-Lavin M., Hermosillo A.G., Rosas M., et al. Circadian studies of autonomic nervous balance in patients with fibromyalgia: a heart rate variability analysis. Arthritis Rheum 1998, 41:1966-1971.
62. Clauw D.J., Radulovic D., Heshmat Y., et al. Heart rate variability as a measure of autonomic function in patients with fibromyalgia (FM) and chronic fatigue syndrome (CSF) [abstract]. J Musculoskelet Pain 1995, 3(suppl 1):78.
63. Ozgocmen S., Yoldas T., Yigiter R., et al. R-R interval variation and sympathetic skin response in fibromyalgia. Arch Med Res 2006, 37(5):630-634.
64. Bou-Holaigah I., Calkins H., Flynn J.A., et al. Provocation of hypotension and pain during upright tilt table testing in adults with fibromyalgia. Clin Exp Rheumatol 1997, 15:239-246.
65. Martinez-Lavin M., Vidal M., Barbosa R.E., et al. Norepinephrine-evoked pain in fibromyalgia. A randomized pilot study. BMC Musculoskelet Dis 2002, 3:2.
66. Marinus J., Van Hilten J.J. Clinical expression profiles of complex regional pain syndrome, fibromyalgia and a-specific repetitive strain injury: more common denominators than pain?. Disabil Rehabil 2006, 28(6):351-362.
67. Maekawa K., Clark G.T., Kuboki T. Intramuscular hypoperfusion, adrenergic receptors, and chronic muscle pain. J Pain 2002, 3(4):251-260.
68. Bonnet M.H., Arand D.L. Heart rate variability: sleep stage, time of night, and arousal influences. Electroencephalogr Clin Neurophysiol 1997, 102:390-396.
69. Naschitz J.E., Mussafia-Priselac R., Kovalev Y., et al. Patterns of hypocapnia on tilt in patients with fibromyalgia, chronic fatigue syndrome, nonspecific dizziness, and neurally mediated syncope. Am J Med Sci 2006, 331(6):295-303.
70. Krieger D.T., Rizzo F. Serotonin mediation of circadian periodicity of plasma 17-hydroxycorticosteroids. Am J Physiol 1969, 217:1703-1707.
71. Holms M.C., Di Renzo G., Beckford U., et al. Role of serotonin in the control of secretion of corticotrophin releasing factor. J Endocrinol 1982, 93:151-160.
72. Wolfe F., Russell I.J., Vipraio G., et al. Serotonin levels, pain threshold and fibromyalgia symptoms in the general population. J Rheumatol 1997, 24:555-559.
73. Russell I.J., Michalek J.E., Vipraio G.A., et al. Serum amino acids in fibrositis/fibromyalgia syndrome. J Rheumatol 1989, 19(suppl):158-163.
74. Russell I.J., Michalek, Vipraio G.A., et al. Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 1992, 19:104-109.
75. Yunus M.B., Dailey J.W., Aldag J.C., et al. Plasma tryptophan and other amino acids in primary fibromyalgia: a controlled study. J Rheumatol 1992, 19:90-94.
76. Yunus M.B., Dailey J.W., Aldag J.C., et al. Plasma and urinary catecholamines in primary fibromyalgia: a controlled study. J Rheumatol 1992, 19:95-97.
77. Russell I.J., Vaeroy H., Javors M., et al. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992, 35:550-556.
78. Russell I.J., Vipraio G.A. Serotonin (5HT) in serum and platelets (PLT) from fibromyalgia patients (FS) and normal controls (NC) [Abstract]. Arthritis Rheum 1994, 37(suppl):S214.
79. Kang Y.-K., Russell I.J., Vipraio G.A., et al. Low urinary 5-hydroxyindole acetic acid in fibromyalgia syndrome: evidence in support of a serotonin-deficiency pathogenesis. Myalgia 1998, 1:14-21.
80. Russell I.J., Vipraio G.A., Acworth I. Abnormalities in the central nervous system (CNS) metabolism of tryptophan (TRY) to 3-hydroxy kynurenine (OHKY) in fibromyalgia syndrome (FS) [Abstract]. Arthritis Rheum 1993, 36:S222.
81. Holman A.J., Myers R.R. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medication. Arthritis Rheum 2005, 52:2495-2505.
82. Yunus M.B., Denko C.W., Masi A.T. Serum beta-endorphin in primary fibromyalgia syndrome: a controlled study. J Rheum 1986, 13(1):183-186.
83. Vaeroy H., Helle R., Forre O., et al. Cerebrospinal fluid levels of B-endorphin in patients with fibromyalgia (fibrositis syndrome). J Rheum 1988, 15:1804-1806.
84. Panerai A.E., Vecchiet J., Panzeri P., et al. Peripheral blood mononuclear cell B-endorphin concentration is decreased in chronic fatigue syndrome and fibromyalgia but not in depression: preliminary report. Clin J Pain 2002, 18(4):270-273.
85. Sorensen J., Bengtsson A., Backman E., et al. Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine and ketamine. Scan J Rheum 1995, 24(6):360-365.
86. Han J.S., Xie C.W. Dynorphin: potent analgesic effect in spinal cord of the rat. Life Sci 1982, 31:1781-1784.
87. Vanderah T., Laughlin T., Lashbrook J., et al. Single intrathecal injections of dynorphin A or des-Tyr-dynorphins produce long lasting allodynia in rats: blockade by MK-801 but not naloxone. Pain 1996, 68:275-281.
88. Laughlin T.M., Vanderah T., Lashbrook J.M., et al. Spinally administered dynorphin A produces long lasing allodynia: involvement of NMDA but not opioid receptors. Pain 1997, 72:253-260.
89. Laughlin T.M., Larson A.A., Wilcox G.L. Mechanisms of induction of persistent nociception by dynorphin. J Pharmacol Exp Ther 2001, 299(1):6-11.
90. Vaeroy H., Nyberg F., Terenius L. No evidence for endorphin deficiency in fibromyalgia following investigation of cerebrospinal fluid (CSF) dynorphin A and met-enkephalin-Arg6-Phe7. Pain 1991, 46:139-143.
91. Coderre T.J., Katz J., Vaccarino A.L., et al. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain 1993, 52:259-285.
92. Tsigos C., Diemel L.T., White A., et al. Cerebrospinal fluid levels of substance P and calcitonin-gene-related peptide: correlation with sural nerve levels and neuropathic signs in sensory diabetic polyneuropathy. Clin Sci Colch 1993, 84:305-311.
93. Galeazza M.T., Garry M.G., Yost H.J., et al. Plasticity in the synthesis and storage of substance P and calcitonin gene-related peptide in primary afferent neurons during peripheral inflammation. Neuroscience 1995, 66:443-458.
94. Vaeroy H., Helle R., Forre O., et al. Elevated CSF levels of substance P and high incidence of Raynaud's phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988, 32:21-26.
95. Russell I.J., Orr M.D., Littman B., et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994, 37:1593-1601.
96. Welin M., Bragee B., Nyberg F., et al. Elevated substance P levels are contrasted by a decrease in met-enkephalin-arg-phe levels in CSF from fibromyalgia patients. J Musculoskelet Pain 1995, 3:4.
97. Bradley L.A., Alberts K.R., Alarcon G.S., et al. Abnormal brain regional cerebral blood flow (rCBF) and cerebrospinal fluid (CSF) levels of substance P (SP) in patients and non-patients with fibromyalgia (FM). Arthritis Rheum 1996, 39(suppl 19):S212.
98. Russell I.J., Fletcher E.M., Vipraio G.A., et al. Cerebrospinal fluid (CSF) substance P (SP) in fibromyalgia: changes in CSF SP over time parallel changes in clinical activity [Abstract]. J Musculoskelet Pain 1998, 6(suppl 2):77.
99. Schwarz M.J., Spath M., Muller-Bardorff H., et al. Relationship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients. Neurosci Lett 1999, 259:196-198.
100. Lindsay R.M., Harmar A.J. Nerve growth factor regulates expression of neuropeptides genes in adult sensory neurons. Nature 1989, 337:362-364.
101. Petty B.G., Cornblath D.R., Adornato B.T., et al. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol 1994, 36:244-246.
102. Giovengo S.L., Russell I.J., Larson A.A. Increased concentrations of nerve growth factor in cerebrospinal fluid of patient with fibromyalgia. J Rheumatol 1999, 26:1564-1596.
103. Vaeroy H., Sakurada T., Forre O., et al. Modulation of pain in fibromyalgia (fibrositis syndrome): cerebrospinal fluid (CSF) investigation of pain related neuropeptides with special reference to calcitonin gene-related peptide (CGRP). J Rheumatol Suppl 1989, 19:94-97.
104. Crofford L.J., Pillemer S.R., Kalogeras K.T., et al. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 1994, 37(11):1583-1592.
105. van Denderen J.C., Boersma J.W., Zeinstra P., et al. Physiological effects of exhaustive physical exercise in primary fibromyalgia syndrome (PFS): is PFS a disorder of neuroendocrine reactivity?. Scan J Rheumatol 1992, 21(1):35-37.
106. Pillemer S.R., Bradley L.A., Crofford L.J., et al. The neuroscience and endocrinology of fibromyalgia. Arthritis Rheum 1997, 40:1928-1939.
107. Yunus M.B., Aldag J.C., Dailey J.W., et al. Interrelationships of biochemical parameters in classification of fibromyalgia syndrome and healthy normal controls. J Musculoskelet Pain 1995, 3(4):15-24.
108. Pall M.L. Common etiology of posttraumatic stress disorder, fibromyalgia, chronic fatigue syndrome and multiple chemical sensitivity via elevated nitric oxide/peroxynitrite. Med Hypotheses 2001, 57(2):139-145.
109. Watkins L.R., Milligan E.D., Maier S.F. Glial activation: a driving force for pathological pain. Trends Neurosci 2001, 24:450-455.
110. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996, 19:312-318.
111. Raivich G., Bluethmann H., Kreutzberg G.W. Signaling molecules and neuroglial activation in the injured central nervous system. Keio J Med 1996, 45:239-247.
112. Sarchielli P., Alberti A., Candeliere A., et al. Glial cell line-derived neurotrophic factor and somatostatin levels in cerebrospinal fluid of patients affected by chronic migraine and fibromyalgia. Cephalalgia 2006, 26(4):409-415.
113. Wallace D.J., Linker-Israeli M., Hallegua D., et al. Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology 2001, 40:743-749.
114. Laske C., Stansky E., Eschweiler G.W., et al. Increased BDNF serum concentration in fibromyalgia with or without depression or antidepressants. J Psychiatr Res 2007, 41(7):600-605.
115. Yaksh T.L. Pharmacology and mechanisms of opioid analgesic activity. Anesthesia: Biologic Foundations 1997, 921-934. Lippincott-Raven, Philadelphia, PA. T.L. Yaksh, C. Lynch, W.M. Zapol (Eds.).
116. Carter B.D., Medzihradsky F. Go mediates the coupling of the mu opioid receptor to adenyl cyclase in cloned neural cells and brain. Proc Natl Acad Sci U S A 1993, 90:4062-4066.
117. Galeotti N., Ghelardini C., Zoppi M., et al. A reduced functionality of Gi proteins as a possible cause of fibromyalgia. J Rheumatol 2001, 28:2298-2304.
118. Galeotti N., Ghelardini C., Zoppi M., et al. Hypofunctionality of Gi proteins as aetiopathogenic mechanism for migraine and cluster headache. Cephalalgia 2001, 21:38-45.
119. Lentjes E.G., Griep E.N., Boersma J.W., et al. Glucocorticoid receptors, fibromyalgia and low back pain. Psychoneuroendocrinology 1997, 22(8):603-614.
120. Crofford L.J., Demitrack M.A. Evidence that abnormalities of central neurohormonal systems are key to understanding fibromyalgia and chronic fatigue syndrome. Rheum Dis Clin North Am 1996, 22:267-284.
121. Griep E.N., Boersma J.W., Lentjes E.G., et al. Function of the hypothalamic-pituitary-adrenal axis in patients with fibromyalgia and low back pain. J Rheumatol 1998, 25:1374-1381.
122. McCain G.A., Tilbe K.S. Diurnal variation in fibromyalgia syndrome: a comparison with rheumatoid arthritis. J Rheumatol 1989, 19(suppl):154-157.
123. Riedel W., Kayka H., Neeck G. Secretory pattern of GH, TSH, thyroid hormones, ACTH, cortisol, FSH and LH in patients with fibromyalgia syndrome following systemic injection of the relevant hypothalamic-releasing hormones. Z Rheumatol 1998, 57(suppl 2):81-87.
124. Griep E.N., Boersma J.W., de Kloet E.R. Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome. J Rheumatol 1993, 20:469-474.
125. Torpy D.J., Papanicolaou D.A., Lotsikas A.J., et al. Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6: a pilot study in fibromyalgia. Arthritis Rheum 2000, 43:872-880.
126. Leal-Cerro A., Povedano J., Astroga R., et al. The growth hormone (GH)-releasing hormone-GH-insulin-like growth factor-1 axis in patients with fibromyalgia syndrome. J Clin Endocrin Metabol 1999, 84:3378-3381.
127. Bagge E., Bengtsson B.A., Carlsson L., et al. Low growth hormone secretion in patients with fibromyalgia-a preliminary report on 10 patients and 10 controls. J Rheumatol 1998, 25:145-148.
128. Adler G.K., Manfredsdottir V.F., Creskoff K.W. Neuroendocrine abnormalities in fibromyalgia. Curr Pain Headache Rep 2002, 6:289-298.
129. Bennett R.M., Clark S.R., Burckhardt C.S., et al. Hypothalamic-pituitary-insulin-like growth factor-1 axis dysfunction in patients with fibromyalgia. J Rheumatol 1997, 24(7):1384-1389.
130. Van Cauter E., Plat L., Copinschi G. Interrelations between sleep and the somatotopic axis. Sleep 1998, 21(6):553-566.
131. Moldofsky H., Scarisbrick P., England R., et al. Musculoskeletal symptoms and non-REM sleep disturbance in patients with "fibrositis" syndrome and healthy subjects. Psychosom Med 1975, 37:341-351.
132. Kato Y., Murakami Y., Sohmiya M., et al. Regulation of human growth hormone secretion and its disorders. Intern Med 2002, 41(1):7-13.
133. Anderson S.M., Shah N., Evans W.S., et al. Short-term estradiol supplementation augments growth hormone (GH) secretory responsiveness to dose-varying GH-releasing peptide infusions in healthy post-menopausal women. J Clin Endocrinol Metab 2001, 86(2):551-560.
134. Cordido F., Dieguez C., Casanueva F.F. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine or hypoglycemia in normal and obese subjects. J Clin Endocrinol Metab 1990, 70(5):1361-1370.
135. Bennett R.M., Cook D.M., Clark S.R., et al. Hypothalamic-pituitary-insulin-like growth factor-1 axis dysfunction in patients with fibromyalgia. J Rheumatol 1997, 24:1384-1389.
136. Neeck G., Riedel W. Thyroid function in patients with fibromyalgia syndrome. J Rheumatol 1992, 19:1120-1122.
137. Press J., Phillip M., Neumann L., et al. Normal melatonin levels in patients with fibromyalgia syndrome. J Rheumatol 1998, 25:551-555.
138. Korszun A., Sackett-Lundeen L., Papadopoulos E., et al. Melatonin levels in women with fibromyalgia and chronic fatigue syndrome. J Rheumatol 1999, 26:2675-2680.
139. Wikner J., Hirsch U., Wetterberg L., et al. Fibromyalgia: a syndrome associated with decreased nocturnal melatonin secretion. Clin Endocrinol 1998, 49(2):179-183.
140. Binder J.R., Swanson S.J., Hammeke T.E., et al. Determination of language dominance using functional MRI: a comparison with the Wada test. Neurology 1996, 46:978-984.
141. Mountz J.M., Bradley L.A., Modell J.G., et al. Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum 1995, 38:926-938.
142. Lineberry C.G., Vierck C.J. Attenuation of pain reactivity by caudate nucleus stimulation in monkeys. Brain Res 1975, 98:119-134.
143. Kwiatek R., Barnden L., Tedman R., et al. Regional cerebral blood flow in fibromyalgia: single-photon-emission computed tomography evidence of reduction in the pontine tegmentum and thalami. Arthritis Rheum 2000, 43:2823-2833.
144. Bradley L.A., Sotolongo A., Alberts K.R., et al. Abnormal regional cerebral blood flow in the caudate nucleus among fibromyalgia patients and non-patients is associated with insidious symptom onset. J Musculoskelet Pain 1999, 7:285-292.
145. Coghill R.C., Talbot J.D., Evans A.C., et al. Distributed processing of pain and vibration by the human brain. J Neurosci 1994, 14:4095-4108.
146. Coghill R.C., Sang C.N., Maisog J.M., et al. Pain intensity processing within the human brain: a bilateral, distributed mechanism. J Neurophysiol 1999, 82:1934-1943.
147. Cianfrini L.R., McKendree-Smith N.L., Bradley L.A., et al. Pain sensitivity and bilateral activation of brain structures during pressure stimulation of patients with fibromyalgia (FM) is not mediated by major depression (DEP). Arthritis Rheum 2001, 44:S395.
148. Mountz J.M., Bradley L.A., Alarcon G.S. Abnormal functional activity of the central nervous system in fibromyalgia syndrome. Am J Med Sci 1998, 315:385-396.
149. Guedj E., Cammilleri S., Miboyet J., et al. Clinical correlate of brain SPECT perfusion abnormalities in fibromyalgia. J Nucl Med 2008, 49(11):1798-1803.
150. Weigent D.A., Bradley L.A., Blalock J.E., et al. Current concepts in the pathophysiology of abnormal pain perception in fibromyalgia. Am J Med Sci 1998, 315:405-412.
151. Pauli P., Wiedemann G., Nickola M. Pain sensitivity, cerebral laterality, and negative affect. Pain 1999, 80:359-364.
152. Valet M., Gundel H., Sprenger T., et al. Patients with pain disorder show gray-matter loss in pain-processing structures: a voxel-based morphometric study. Psychosom Med 2009, 71(1):49-56.
153. Kuchinad A., Schweinhardt P., Seminowicz D.A., et al. Accelerated brain gray matter loss in fibromyalgia patients: premature aging of the brain?. J Neurosci 2007, 27(15):4004-4007.
154. Schmidt-Wilcke T., Lluerding R., Weigand T., et al. Striatal grey matter increase in patients suffering from fibromyalgia-a voxel-based morphometry study. Pain 2007, 132:S109-S116.
155. Schmidt-Wilcke T. Variations in brain volume and regional morphology associated with chronic pain. Curr Rheumatol Rep 2008, 10(6):467-474.
156. Lutz J., Jager L., de Quervain D., et al. White and gray matter abnormalities in the brain of patients with fibromyalgia. Arthritis Rheum 2008, 58(12):3960-3969.
157. Elvin A., Siosteen A.K., Nilsson A., et al. Decreased muscle blood flow in fibromyalgia patients during standardized muscle exercise: a contrast media enhanced colour Doppler study. Eur J Pain 2006, 10(2):137-144.
158. Kasikcioglu E., Dinler M., Berker E. Reduced tolerance of exercise in fibromyalgia may be a consequence of impaired microcirculation initiated by deficient action of nitric oxide. Med Hypotheses 2006, 66(5):950-952.
159. Yunus M.B., Kalyan-Raman U.P., Masi A.T., et al. Electron microscopic studies of muscle biopsy in primary fibromyalgia syndrome: a controlled and blinded study. J Rheumatol 1989, 16:97-101.
160. Bengtsson A., Henriksson K.G., Larsson J. Muscle biopsy in primary fibromyalgia: light microscopical and histochemical findings. Scand J Rheumatol 1986, 15:106.
161. Drewes A.M., Andreasen A., Schroder H.D., et al. Muscle biopsy in fibromyalgia. Scand J Rheumatol 1992, 94(suppl):20.
162. Bengtsson A., Henriksson K.G., Larsson J. Reduced high-energy phosphate levels in the painful muscles of patients with primary fibromyalgia. Arthritis Rheum 1986, 29:817-821.
163. Simms R.W. Fibromyalgia is not a muscle disorder. Am J Med Sci 1998, 315:346-350.
164. Simms R.W. Is there muscle pathology in fibromyalgia syndrome. Rheum Dis Clin North Am 1996, 22:245-266.
165. Branco J.C., Atalaia A., Paiva T. Sleep cycles and alpha-delta sleep in fibromyalgia syndrome. J Rheumatol 1994, 21:1113-1117.
166. Drewes A.M., Gade J., Nielsen K.D., et al. Clustering of sleep electroencephalopathic patterns in patients with the fibromyalgia syndrome. Br J Rheumatol 1995, 34:1151-1156.
167. Perlis M.L., Giles D.E., Bootzin R.R., et al. Alpha sleep and information processing, perception of sleep, pain and arousability in fibromyalgia. Int J Neurosci 1997, 89:265-280.
168. Moldofsky H., Lue F.A., Smythe H.A. Alpha EEG sleep and morning symptoms in rheumatoid arthritis. J Rheumatol 1983, 10:373-379.
169. Moldofsky H., Saskin P., Lue F.A. Sleep symptoms in fibrositis syndrome after a febrile illness. J Rheumatol 1988, 15:1701-1704.
170. Moldofsky H. Sleep and pain. Sleep Med Rev 2001, 5(5):385-396.
171. Izuierdo A.S., Bocos Terraz P., Bancalero Flores J.L., et al. Is there an association between fibromyalgia and below-normal levels of urinary cortisol?. BMC Res Notes 2008, 1(1):134.
172. Ahles T.A., Yunus M.B., Masi A.T. Is chronic pain a variant of depressive disease? The case of primary fibromyalgia syndrome. Pain 1987, 29:105-111.
173. Ahles T.A., Khan S.A., Yunus M.B., et al. Psychiatric status of patients with primary fibromyalgia, patients with rheumatoid arthritis and subjects without pain: a blind comparison of DSM-III diagnoses. Am J Psychiatry 1991, 148:1721-1726.
174. Clark S., Campbell S.M., Forehand M.E., et al. Clinical characteristics of fibrositis. II. A "blinded", controlled study using standard psychological tests. Arthritis Rheum 1985, 28:132-137.
175. Kirmayer L.J., Robbins J.M., Kapusta M.A. Somatization and depression in fibromyalgia syndrome. Am J Psychiatry 1988, 145:950-954.
176. Hudson J.I., Hudson M.S., Pliner L.F., et al. Fibromyalgia and major affective disorder: a controlled phenomenology and family history study. Am J Psychiatry 1985, 142:441-446.
177. Hudson J.I., Goldenberg D.L., Pope H.G., et al. Comorbidity of fibromyalgia with medical and psychiatric disorders. J Rheumatol Suppl 1992, 92:363-367.
178. Aaron L.A., Bradley L.A., Alarcon G.S., et al. Psychiatric diagnoses in patients with fibromyalgia are related to health care-seeking behavior rather than to illness. Arthritis Rheum 1996, 39:436-445.
179. White K.P., Nielson W.R., Harth M., et al. Chronic widespread musculoskeletal pain with or without fibromyalgia: psychological distress in a representative community adult sample. J Rheumatol 2002, 29:588-594.
180. Ahles T.A., Yunus M.B., Riley S.D., et al. Psychological factors associated with primary fibromyalgia syndrome. Arthritis Rheum 1984, 27:1101-1106.
181. Dailey P.A., Bishop G.D., Russell I.J., et al. Psychological stress and the fibrositis/fibromyalgia syndrome. J Rheumatol 1990, 17:1380-1385.
182. Missole C., Toroni F., Sigala S., et al. Nerve growth factor in the anterior pituitary: localization in mammotroph cells and co-secretion with prolactin by a dopamine-regulated mechanism. Proc Natl Acad Sci U S A 1996, 93:4240-4245.
183. Lindsay R.M., Lockett C., Sternberg J., et al. Neuropeptide expression in cultures of adult sensory neurons: modulation of substance P and calcitonin gene-related peptide levels by nerve growth factor. Neuroscience 1989, 33:53-65.
184. Goebel M.U., Mills P.J., Irwin M.R., et al. Interleukin-6 and tumor necrosis factor-alpha production after acute psychological stress, exercise and infused isoproterenol: differential effects and pathways. Psychosom Med 2000, 62:591-598.
185. Davis M.C., Zautra A.J., Reich J.W. Vulnerability to stress among women in chronic pain from fibromyalgia and osteoarthritis. Ann Behav Med 2001, 23:215-226.
186. Adler G.K., Kinsley B.T., Hurwitz S., et al. Reduced hypothalamic-pituitary and sympa-thoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. Am J Med 1999, 106:534-543.
187. Schatzberg A.F., Rothschild A.J., Stahl J.B., et al. The dexamethasone suppression test: identification of subtypes of depression. Am J Psychiatry 1983, 140:88-91.
188. Banki C.M., Bissette G., Arato M., et al. CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. Am J Psychiatry 1987, 144:873-877.
189. Maes M., Lin A., Bonaccorso S., et al. Increased 24-hour urinary cortisol excretion in patients with post-traumatic stress disorder and patients with major depression, but not in patients with fibromyalgia. Acta Psychiatr Scand 1998, 98:328-335.
190. Alexander R.W., Bradley L.A., Alarcon G.S., et al. Sexual and physical abuse in women with fibromyalgia: association with outpatients health care utilization and pain medication usage. Arthritis Care Res 1998, 11:102-115.
191. Goldberg R.T., Pachas W.N., Keith D. Relationship between traumatic events in childhood and chronic pain. Disabil Rehabil 1999, 21:23-30.
192. McBeth J., Macfarlane G.J., Benjamin S., et al. The association between tender points, psychological distress, and adverse childhood experiences: a community based study. Arthritis Rheum 1999, 42:1397-1404.
193. Boisset-Pioro M.H., Esdaile J.M., Fitzcharles M.A. Sexual and physical abuse in women with fibromyalgia syndrome. Arthritis Rheum 1995, 38:235-241.
194. Fassbender K., Samborsky W., Kellner M., et al. Tender points, depressive and functional symptoms: comparison between fibromyalgia and major depression. Clin Rheumatol 1997, 16:76-79.
195. Golding J.M. Sexual-assault history and long-term physical health problems: evidence from clinical and population epidemiology. Curr Dir Psychol Sci 1999, 8(6):191-194.
196. Leavitt F., Katz R.S., Mills M., et al. Cognitive and dissociative manifestations in fibromyalgia. J Clin Rheumatol 2002, 8:77-84.
197. White K.P., Nielson W.R., Harth M., et al. Does the label "fibromyalgia" alter health status, function, and health service utilization? A prospective, within-group comparison in a community cohort of adults with chronic widespread pain. Arthritis Care Res 2002, 47(3):260-265.
198. Pelligrino M.J., Waylonis G.W., Sommer A. Familial occurrence of primary fibromyalgia. Arch Phys Med Rehabil 1989, 70:61-63.
199. Buskila D., Neumann L. Fibromyalgia syndrome (FM) and nonarticular tenderness in relatives of patients with FM. J Rheumatol 1997, 24:941-944.
200. Offenbaecher M., Bondy B., de Jonge S., et al. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum 1999, 42:2482-2488.
201. Martinez J.E., Ferraz M.B., Sato E.I., et al. Fibromyalgia versus rheumatoid arthritis: a longitudinal comparison of the quality of life. J Rheumatol 1995, 22:270-274.
202. Henriksson C.M. Longterm effects of fibromyalgia on everyday life. A study of 56 patients. Scand J Rheumatol 1994, 23:36-41.
203. Burckhardt C.S., Clark S.R., Bennett R.M. Fibromyalgia and quality of life: a comparative analysis. J Rheumatol 1993, 20:475-479.
204. Wolfe F., Anderson J., Harkness D., et al. Work and disability status of persons with fibromyalgia. J Rheumatol 1997, 24:1171-1178.
205. Cathey M.A., Wolfe F., Kleinheksel S.M. Functional ability and work status in patients with fibromyalgia. Arthritis Care Res 1988, 1:25-33.
206. Lundberg G., Gerdle B. Tender point scores and their relations to signs of mobility, symptoms, and disability in female home care personnel and the prevalence of fibromyalgia syndrome. J Rheumatol 2002, 29:603-613.
207. Leidberg G.M., Henriksson C.M. Factors of importance for work disability in women with fibromyalgia: an interview study. Arthritis Care Res 2002, 47:266-274.
208. Wolfe F., Ross K., Anderson J., Russell I.J. Aspects of fibromyalgia in the general population: sex, pain threshold and fibromyalgia symptoms. J Rheumatol 1995, 22:151-156.
209. Gracely R.H., Grant M.A., Giesecke T. Evoked pain measures in fibromyalgia. Best Pract Res Clin Rheumatol 2003, 17(4):593-609.
210. Petzke F., Khine A., Williams D., et al. Dolorimetry performed at 3 paired tender points highly predicts overall tenderness. J Rheumatol 2001, 28(11):2568-2569.
211. 2 laser stimulation in subjects with fibromyalgia syndrome. Pain 1994, 58(2):185-193.
212. Kosek E., Hansson P. Modilatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyalgia and healthy subjects. Pain 1997, 70(1):41-51.
213. Geisser M.E., Casey K.L., Brucksch C.B., Ribbens C.M., Appleton B.B., Crofford L.J. Perception of noxious and innocuous heat stimulation among healthy women and women with fibromyalgia: association with mood, somatic focus, and catastrophizing. Pain 2003, 102(3):243-250.
214. Arroyo J.F., Cohen M.L. Abnormal responses to electrocutaneous stimulation in fibromyalgia. J Rheumatol 1993, 20(11):1925-1931.
215. Geisser M.E., Gracely R.H., Giesecke T., Petzke F.W., Williams D.A., Clauw D.J. The association between experimental and clinical pain measures among persons with fibromyalgia and chronic fatigue syndrome. Eur J Pain 2007, 11(2):202-207.
216. Damasio A., Damasio H., Tranel D. Persistence of feelings and sentience after bilateral damage of the insula. Cereb Cortex 2013, 23(4):833-846.
217. Staud R., Smitherman M.L. Peripheral and central sensitization in fibromyalgia: pathogenetic role. Curr Pain Headache Rep 2002, 6(4):259-266.
218. Elvin A., Siosteen A.K., Nilsson A., Kosek E. Decreased muscle blood flow in fibromyalgia patients during standardized muscle exercise: a contrast media enhanced colour Doppler study. Eur J Pain 2006, 10(2):137-144.
219. Yunus M.B., Kalyan-Raman U.P., Masi A.T., Aldag J.C. Electron microscopic studies of muscle biopsy in primary fibromyalgia syndrome: a controlled and blinded study. J Rheumatol 1989, 16(1):97-101.
220. Kim S.H., Jang T.J., Moon I.S. Increased expression of N-methyl-d-aspartate receptor subunit 2D in the skin of patients with fibromyalgia. J Rheumatol 2006, 33(4):785-788.
221. Woolf C.J., Thompson S.W. The induction and maintenance of central sensitization is dependent on N-methyl-d-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain 1991, 44:293-299.
222. Stein C., Machelska H., Binder W., et al. Peripheral opioid analgesia. Curr Opin Pharmacol 2001, 1:62-65.
223. Brenman J.E., Bredt D.S. Synaptic signaling by nitric oxide. Curr Opin Neurobiol 1997, 7:374-378.
224. Schuman E.M., Madison D.V. Nitric oxide and synaptic function. Ann Rev Neurosci 1994, 17:153-183.
225. Aimar P., Pasti L., Carmignoto G., et al. Nitric oxide-producing islet cells modulate the release of sensory neuropeptides in the rat substantia gelatinosa. J Neurosci 1998, 18:10357-10388.
226. Sendur O.F., Turan Y., Tasstaban E., et al. Serum antioxidants and nitric oxide levels in fibromyalgia: a controlled study. Rheumatol Int 2009, 29(6):629-633.
227. Price D.D., Mao J., Frenk H., et al. The N-methyl-d-aspartate receptor antagonist dextromethorphan selectively reduces temporal summation of second pain in man. Pain 1994, 59:165-174.
228. Price D.D., Hu J.W., Dubner R., et al. Peripheral suppression of first pain and central summation of second pain evoked by noxious heat pulses. Pain 1977, 3:57-68.
229. Price D.D. Characteristics of second pain and flexion reflexes indicative of prolonged central summation. Exp Neurol 1972, 37:371-387.
230. Graven-Nielsen T., Kendall S.A., Henriksson K.G., et al. Ketamine reduces muscle pain, temporal summation and referred pain in fibromyalgia patients. Pain 2000, 85:483-491.
231. Yunus M.B., Inanici F. Clinical characteristics and biopathophyisological mechanisms of fibromyalgia syndrome. Myofascial Pain and Fibromyalgia Syndrome 2001, 351-378. Churchill Livingstone, London, UK. P.E. Baldry (Ed.).
232. Hurtig I.M., Raak R.I., Kendall S.A., Gerdle B., Wahren L.K. Quantitative sensory testing in fibromyalgia patients and in healthy subjects: identification of subgroups. Clin J Pain 2001, 17(4):316-322.
233. Granot M., Buskila D., Granovsky Y., Sprecher E., Neumann L., Yarnitsky D. Simultaneous recording of late and ultra-late pain evoked potentials in fibromyalgia. Clin Neurophysiol 2001, 112(10):1881-1887.
234. Wang H., Clauw D., Zubieta J., Harris R.E. Evoked pain brain response is associated with reduced opioid receptor binding in fibromyalgia. Am Col Rheumatol 2012, 64. [Abstract 2450].
235. Staud R., Vierck C.J., Cannon R.L., Mauderli A.P., Price D.D. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 2001, 91(1-2):165-175.
236. Baraniuk J.N., Whalen G., Cunningham J., Clauw D.J. Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain. BMC Musculoskelet Disord 2004, 5:48.
237. Desmeules J.A., Cedraschi C., Rapiti E., et al. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum 2003, 48(5):1420-1429.
238. Giesecke T., Williams D.A., Harris R.E., et al. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum 2003, 48(10):2916-2922.
239. Banic B., Peterson-Felix S., Andersen O.K., et al. Evidence for spinal cord hypersensitivity in chronic pain after whiplash injury and in fibromyalgia. Pain 2004, 107(1-2):7-15.
240. Petzke F., Jensen K.B., Kosek E., et al. Using fMRI to evaluate the effects of milnacipran on central pain processing in patients with fibromyalgia. Scan J Pain 2013, 4(2):65-74.
241. Russo E.B. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment resistant conditions?. Neuroendocrinol Lett 2004, 25:31-39.
242. Corchero J., Manzanares J., Fuentes J.A. Cannabinoid/opioid crosstalk in the central nervous system. Crit Rev Neurobiol 2004, 16:159-172.
243. Salio C., Fischer J., Franzoni M.F., et al. CB1-cannabinoid and mu-receptor co-localization on postsynaptic target in the rat dorsal horn. Neuroreport 2001, 12:3639-3692.
244. Skrabek R.Q., Galimova L., Ethans K., et al. Nabilone for the treatment of pain in fibromyalgia. J Pain 2008, 9(2):164-173.
245. Ko G., Wine W. Chronic pain and cannabinoids: a survey study of current fibromyalgia treatment approaches together with an overview and case studies of a new "old" treatment approach. Pract Pain Manag 2005, 1:1-8.
246. Granges G., Littlejohn G. Prevalence of myofascial pain syndrome in fibromyalgia syndrome and regional pain syndrome: a comparative study. J Musculoskelet Pain 1993, 1(2):19-35.
247. Gerwin R.D. A study of 96 subjects examined both for fibromyalgia and myofascial pain [Abstract]. J Musculoskelet Pain 1995, 3(suppl 1):21.
248. Bennett R.M. Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc 1999, 74:385-398.
249. Martinez-Lavin M. Is fibromyalgia a generalized reflex sympathetic dystrophy?. Clin Exp Rheumatol 2001, 19:1-3.
250. Henriksson K.G. Hypersensitivity in muscle pain syndromes. Curr Pain Headache Rep 2003, 7:426-432.
251. Sorensen J., Graven-Nielsen T., Hendriksson K.G., et al. Hyperexcitability in fibromyalgia. J Rheumatol 1998, 25:152-155.
252. Wright A., Graven-Nielsen T., Davies, et al. Temporal summation of pain from skin, muscle and joint following nociceptive ultrasonic stimulation in humans. Exp Brain Res 2002, 144:475-482.
253. Turk D.C. The potential of treatment matching for subgroups of patients with chronic pain: lumping versus splitting. Clin J Pain 2005, 21(1):44-55.
254. Dobkin P.L., Sita A., Sewitch M.J. Predictors of adherence to treatment in women with fibromyalgia. Clin J Pain 2006, 22(3):286-294.
255. Melillo N., Corrado A., Quarta L., et al. Fibromyalgic syndrome: new perspectives in rehabilitation and management. A review. Minerva Med 2005, 96(6):417-423.
256. Arnold L.M. Biology and therapy of fibromyalgia. New therapies in fibromyalgia. Arthritis Res Ther 2006, 8(4):212.
257. Wolfe F., Anderson J., Harkness D., et al. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum 1997, 40:1560-1570.
258. Goldenberg D.L., Felson D.T., Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 1986, 29:1371-1377.
259. Yunus M.B., Masi A.T., Aldag J.C. Short term effects of ibuprofen in primary fibromyalgia syndrome: a double blind, placebo controlled trial. J Rheumatol 1989, 16:527-532.
260. Clark S., Tindall E., Bennett R.M. A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis. J Rheumatol 1985, 12:980-983.
261. Ang D., Wilke W.S. Diagnosis, etiology and therapy of fibromyalgia. Compr Ther 1999, 25:221-227.
262. Krsnich-Shriwise S. Fibromyalgia syndrome: an overview. Phys Ther 1997, 77:68-75.
263. Buskila D. Drug therapy. Baillieres Best Pract Res Clin Rheumatol 1999, 13:479-485.
264. Russell I.J., Kamin M., Sager D., et al. Efficacy of Ultram (Tramadol HCL) treatment of fibromyalgia syndrome: preliminary analysis of a multi-center, randomized, placebo-controlled study. Arthritis Rheum 1997, 40(suppl 9):S117.
265. Rauck R.L., Ruoff G.E., McMillen J.I. Comparison of tramadol and acetaminophen with codeine for long-term pain management in elderly patients. Curr Ther Res 1994, 55:1417-1431.
266. Biasi G., Manca S., Manganelli S., et al. Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo. Int J Clin Pharacol Res 1998, 18:13-19.
267. Russell I.J. Efficacy of ULTRAM (Tramadol Hcl) treatment of fibromyalgia syndrome (FMS): secondary outcomes report. TPS-FM Study Group [Abstract]. J Musculoskelet Pain 1998, 6(suppl 2):147.
268. Gasse C., Derby L., Vasilakis-Scaramozza C., et al. Incidence of first-time idiopathic seizures in users of tramadol. Pharacotherapy 2000, 20:629-634.
269. Leventhal L.G. Management of fibromyalgia. Ann Intern Med 1999, 131:850-858.
270. Rospond R.M., Spellman J. Fibromyalgia and the role of the pharmacist. U. S. Pharmacist 1997, 22:41-52.
271. Brown R.L., Fleming M.F., Patterson J.J. Chronic opioid analgesic therapy for chronic low back pain. J Am Board Fam Pract 1996, 9:191-204.
272. A consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin J Pain 1997, 13:6-8. The use of opioids for the treatment of chronic pain.
273. Portenoy R.K. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage 1996, 11:203-217.
274. McClain D.A. The effects of Tizanidine HCL (Zanaflex R) in patients with Fibromyalgia. Current Trends in the Diagnosis and Treatment of Chronic Neuromuscular Pain Syndromes. Am Acad Pain Manag. Precom International August 2000, G.W. Jay, J.C. Drusz, D.R. Longmire, D.A. McLain (Eds.).
275. Hong C.Z., Hsueh T.C. Difference in pain relief after trigger point injections in myofascial pain patients with and without fibromyalgia. Arch Phys Med Rehabil 1996, 77:1161-1166.
276. Yunus M.B. Fibromyalgia syndrome: is there any effective therapy?. Consultant 1996, 36:1279-1286.
277. Raphael J.H., Southall J.L., Treharne G.J., et al. Efficacy and adverse effects of intravenous lignocaine therapy in fibromyalgia syndrome. BMC Musculoskelet Disord 2002, 3(1):21.
278. Staud R. Are tender point injections beneficial: the role of tonic nociception in fibromyalgia. Curr Pharm Des 2006, 12(1):23-27.
279. Sorensen J., Bengtsson A., Ahlner J., et al. Fibromyalgia-are there different mechanisms in the processing of pain? A double blind crossover comparison of analgesic drugs. J Rheumatol 1996, 24:1615-1621.
280. Henriksson K.G., Sorensen J. The promise of N-methyl-d-aspartate receptor antagonists in fibromyalgia. Rheum Dis Clinics North Am 2002, 28(2):1-7.
281. Stuad R., Vierck C.J., Robinson M.E., et al. Effects of the N-methyl-d-aspartate receptor antagonist dextromethorphan on temporal summation of pain are similar in fibromyalgia patients and normal controls subjects. J Pain 2005, 6(5):323-332.
282. Cohen S.P., Verdolin M.H., Chang A.S., et al. The intravenous ketamine test predicts subsequent response to an oral dextromethorphan treatment regimen in fibromyalgia patients. J Pain 2006, 7(6):391-399.
283. Maizels M., McCarberg B. Antidepressants and antiepileptic drugs for chronic non-cancer pain. Am Fam Physician 2005, 71(3):483-490.
284. Scudds R.A., McCain G.A., Rollman G.B., et al. Improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline. J Rheumatol 1989, 19(suppl):98-103.
285. Carette S., McCain G.A., Bell D.A., et al. Evaluation of amitriptyline in primary fibrositis. A double blind, placebo-controlled study. Arthritis Rheum 1986, 29(5):655-659.
286. Jaeschke R., Adachi J., Guyatt G., et al. Clinical usefulness of amitriptyline in fibromyalgia: the results of 23 N-of-1 randomized controlled trials. J Rheumatol 1991, 18(3):447-451.
287. Maurizio S.J., Rogers J.L. Recognizing and treating fibromyalgia. Nurse Pract 1997, 22:18-33.
288. Simms R.W. Fibromyalgia syndrome: current concepts in pathophysiology, clinical features, and management. Arthritis Care Res 1996, 9:315-328.
289. Wallace D.J. The fibromyalgia syndrome. Ann Med 1997, 29:9-21.
290. Creamer P. Effective management of fibromyalgia. J Musculoskelet Med 1999, 16:622.
291. Wysenbeek A.J., Mor F., Lurie Y., et al. Imipramine for the treatment of fibrositis: a therapeutic trial. Ann Rheum Dis 1985, 44:752-753.
292. Nishishinya B., Urrutia G., Walitt B., et al. Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy. Rheumatology (Oxford) 2008, 47(12):1741-1746.
293. Reynolds W.J., Moldofsky H., Saskin P., et al. The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia. J Rheumatol 1991, 18(3):452-454.
294. Bennett R.M., Gatter R.A., Campbell S.M., et al. A comparison of cyclobenzaprine and placebo in the management of fibrositis. A double blind controlled study. Arthritis Rheum 1988, 31(12):1535-1542.
295. Carrette S., Bell M.J., Reynolds W.J., et al. Comparison of amitriptyline, cyclobenzaprine and placebo in the treatment of fibromyalgia. Arthritis Thrum 1994, 37(1):32-40.
296. Santandrea S., Montrone F., Sarzi-Puttini P., et al. A double-blind crossover study of two cyclobenzaprine regimens in primary fibromyalgia syndrome. J Int Med Res 1993, 21:74-80.
297. McCain G.A. A cost-effective approach to the diagnosis and treatment of fibromyalgia. Rheum Dis Clin North Am 1996, 22:323-349.
298. Goldenberg D., Mayskiy M., Mossey C., et al. A randomized, double blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996, 39(11):1852-1859.
299. Anderberg U.M., Marteinsdottir I., von Knorring L. Citalopram in patients with fibromyalgia-a randomized, double-blind, placebo controlled study. Eur J Pain 2000, 4(1):27-35.
300. Alberts K., Bradley L., Alarcon G., et al. Sertraline hydrochloride alters pain threshold, sensory discrimination ability and functional brain activity in patients with fibromyalgia (FM): a randomized controlled trial. Arthritis Rheum 1998, 41(suppl):S259.
301. Gonzalez-Viejo M.A., Avellanet M., Henrandez-Morcuende M.I. A comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment. Ann Readapt Med Phys 2005, 48(8):610-615.
302. Wolfe F., Cathey M.A., Hawlet D.J. A double blind placebo controlled trial of Fluoxetine in fibromyalgia. Scand J Rheumatol 1994, 23:255-259.
303. Dwight M.M., Arnold L.M., O'Brien H., et al. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics 1998, 39:14-17.
304. Clauw D.J. Treating fibromyalgia: science vs. art. Am Fam Physician 2000, 62:1492-1494.
305. Arnold L.M., Rosen A., Pritchett Y.L., et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005, 119:5-15.
306. Russell I.J., Mease P., Smith T., et al. The safety and efficacy of duloxetine for the treatment of fibromyalgia syndrome in patients with or without major depressive disorder: results from a 6-month randomized, double-blind, placebo-controlled, fixed-dosed trial [Abstract #103]. J Musculoskelet Pain 2007, 15(suppl 13):58.
307. Chappell AS, Bradley LA, Wiltse C, et al. Duloxetine 6-120mg versus placebo in the treatment of fibromyalgia syndrome. Program and abstracts of the American College of Rheumatology (ACR) 71st Annual Meeting, November 6-11, 2007, Boston, MA [Abstract #1543].
308. Zijlstra T.R., Barendregt P.T., van De Laar M.A. Venlafaxine in fibromyaglia: results of a randomized placebo-controlled double-blind trial. Arthritis Rheum 2002, 46:S105.
309. Rao SG, King T, Porreca F. Elucidation of the analgesic efficacy of milnacipran in chronic pain. Presented at the International Association for the Study of Pain's Tenth World Congress on Pain, San Diego, CA, 2002.
310. Vitton O., Gendreau M., Gendreau J., et al. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 2004, 19(suppl 1):S27-S35.
311. Clauw D.J., Mease P., Paolmer R.H., et al. Milnacipran for the treatment of fibromyalgia in adults: a 15 week, multicenter, randomized, double-blind, placebo-controlled multiple-dose clinical trial. Clin Ther 2008, 30(11):1988-2004.
312. Samborski W., Sezanska-Szpera M., Rybakowski J.K. Open trial of mirtazapine in patients with fibromyalgia. Pharacopsychiatry 2004, 37(4):168-170.
313. Arnold L.M., Keck P.E., Welge J.A. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics 2000, 41(2):104-113.
314. O'Malley P.G., Balden E., Tomkins G., et al. Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Int Med 2000, 15(9):659-666. Cochrane Database Syst Rev 2002;4:05463.
315. Jackson J.L., O'Malley P.G., Kroenke K. Antidepressants and cognitive-behavioral therapy for symptom syndromes. CNS Spectr 2006, 11(3):121-122.
316. Wiffen P., Collins S., McQuay H., et al. Anticonvulsant drugs for acute and chronic pain (Cochrane Review). The Cochrane Library 2002, Update Software, Oxford.
317. Duan R, Diri E, Young JP, et al. Efficacy of pregabalin monotherapy for relief of pain associated with fibromyalgia: time course and durability of pain results of a 14-week, double-blind, placebo controlled trial. Program and abstracts of the American College of Rheumatology (ACR) 71st Annual Meeting, November 6-11, 2007, Boston, MA [Abstract #715].
318. Duan R, Florian H, Young JP, et al. Pregabalin monotherapy for management of fibromyalgia: analysis of two double-blind, randomized, placebo-controlled trials. Program and Abstracts of the American College of Rheumatology (ACR) 71st Annual Meeting, November 6-11, 2007, Boston, MA [Abstract #1524].
319. Crofford L.J., Rowbotham M.C., Mease P.J., et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005, 52(4):1264-1273.
320. Florian H, Young JP, Haig G, et al. Efficacy and safety of pregabalin as long-term treatment of pain associated with fibromyalgia: a 1-year, open-label study. Program and Abstracts of the American College of Rheumatology (ACR) 71st Annual Meeting, November 6-11, 2007, Boston, MA [Abstract #1523].
321. Simpson SL, Young JP, Haig G, et al. Pregabalin therapy for durability of meaningful relief of fibromyalgia. Program and abstracts of the American College of Rheumatology (ACR) 71st Annual Meeting, November 6-11, 2007, Boston, MA [Abstract #1522].
322. Hrycaj P., Stratz T., Mennet P., et al. Pathogenic aspects of responsiveness to ondansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome-a preliminary study. J Rheumatol 1996, 23:1418-1423.
323. 3 receptor antagonist. German Fibromyalgia Study Group. Scand J Rheumatol 2000, 113(suppl):49-54.
324. 3 blockers in the treatment of the primary fibromyalgia syndrome: a 10 day open study with Tropisetron at a low dose. Mater Med Pol 1996, 28:17-19.
325. Spath M., Stratz T., Neeck G., et al. Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia. Scand J Rheumatol 2004, 33(4):267-270.
326. Stratz T., Feibich B., Haus U., et al. Influence of tropisetron on the serum substance P levels in fibromyalgia patients. Scand J Rheumatol Suppl 2004, 119:41-43.
327. Russell I.J., Fletcher E.M., Michalek J.E., et al. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam: a double blind, placebo-controlled study. Arthritis Rheum 1991, 34:552-560.
328. Hench P.K., Cohen R., Mitler M.M. Fibromyalgia: effects of amitriptyline, temazepam and placebo on pain and sleep [Abstract]. Arthritis Rheum 1989, 32(suppl):S47.
329. Rico-Villademoros F., Hidalgo J., Dominguez I., et al. Atypical antipsychotics in the treatment of fibromyalgia: a case series with olanzapine. Prog Neuropsycholpharmacol Biol Psychiatry 2005, 29(1):161-164.
330. Moldofsky H., Scarisbrick P. Induction of neurasthenic musculoskeletal pain syndrome by selective sleep stage deprivation. Psychosom Med 1976, 38:35-44.
331. Moldofsky H. Sleep and musculoskeletal pain. Am J Med 1986, 81(suppl 3A):85-89.
332. Cote K.A., Moldofsky H. Sleep daytime symptoms, and cognitive performance in patients with fibromyalgia. J Rheumatol 1997, 24:2014-2023.
333. Drewes A.M., Nielsen K.D., Taagholt S.J., et al. Sleep intensity in fibromyalgia: focus on the microstructure of the sleep process. Br J Rheumatol 1995, 34:629-635.
334. Moldofsky H., Lue F.A., Mously C., et al. The effect of zolpidem in patients with fibromyalgia: a dose ranging, double blind placebo controlled, modified crossover study. J Rheumatol 1996, 23(3):529-533.
335. Drewes A.M., Andreasen A., Jennum P., et al. Zopiclone the treatment of sleep abnormalities in fibromyalgia. Scan J Rheumatol 1991, 20(4):288-293.
336. Gronblad M., Nykanen J., Konttinen Y., et al. Effect of zopiclone on sleep quality, morning stiffness, widespread tenderness and pain and general discomfort in primary fibromyalgia patients. A double blind randomized trial. Clin Rheumatol 1993, 12(2):186-191.
337. Moldofsky H., Benz B., Luc F., et al. Comparison of chlorpromazine and l-tryptophan on sleep, musculoskeletal pain, and mood in fibrositis syndrome. Sleep Res 1976, 5:76.
338. Gebhart B., Jorgenson J.A. Benefit of ribose in a patient with fibromyalgia. Pharmacotherapy 2004, 24(11):1646-1648.
339. Finckh A., Berner I.C., Aubry-Rozier B., et al. A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. J Rheumatol 2005, 32(7):1336-1340.
340. Tavoni A., Vitali C., Bombardieri S., et al. Evaluation of S-adenosylmethionine in primary fibromyalgia. A double blind crossover study. Am J Med 1987, 83(5A):107-110.
341. Tavoni A., Jeracitano G., Cirigloiano G. Evaluation of S-adenosylmethionine in secondary fibromyalgia: a double blind study [letter]. Clin Exp Rheumatol 1998, 16(1):106-107.
342. Caruso I., Sarzi Puttinji P., Cazzola M., et al. Double blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 1990, 18:201-209.
343. Bessette L., Carette S., Fossel A.H., et al. A placebo controlled crossover trial of subcutaneous salmon calcitonin in the treatment of patients with fibromyalgia. Scand J Rheumatol 1998, 27:112-116.
344. Bennett R.M., Clark S.C., Walczyk J. A randomized, double blind, placebo controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 1998, 104:227-231.
345. Wood P.B. Fibromyalgia syndrome: a central role for the hippocampus-a theoretical construct. J Musculoskelet Pain 2004, 12(1):19-26.
346. Dziedzicka-Wasylewska M., Ferrari F., Johnson R.D., et al. Mechanisms of action of pramipexole: effects on receptors. Rev Contemp Pharmacother 2001, 12(1-2):1-31.
347. Holman A.J. Treatment of fibromyalgia with the dopamine agonist ropinirole: a 14-week double-blind, pilot, randomized controlled trial with 14-week blinded extension. Arthritis Rheum 2004, 50(9). (suppl) A1870.
348. Janzen V., Scudds R.A. Sphenopalatine blocks in the treatment of pain in fibromyalgia and myofascial pain. Laryngoscope 1997, 107:1420-1422.
349. Bengtsson A., Bengtsson M. Regional sympathetic blockade in primary fibromyalgia. Pain 1988, 33:161-167.
350. Yunus M.B., Aldag J.C. Restless legs syndrome and leg cramps in fibromyalgia syndrome: a controlled study. Br Med J 1996, 312:1339.
351. McAfee D.A., Hadgraft J., Lane M.E. Rotigotine: the first new chemical entity for transdermal drug delivery. Eur J Pharm Biopharm 2014, 88(3):586-593.
352. Benitez A., Edens H., Fishman J., et al. Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome. Ann NY Acad Sci 2014, 1329(1):45-66.
353. Sun Y., van Valkenhoef G., Morei T. A mixed comparison of gabapentin, encarbil, pramipexole, ropinirole and rotigotine in moderate to severe restless legs syndrome. Curr Med Res Opin 2014, 30(11):2267-2278.
354. Kaplan P.W., Allen R., Bucholz D.W., et al. A double blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep 1993, 16:713-716.
355. Becker P.M., Jamieson A.O., Brown W.D. Dopaminergic agents in restless legs syndrome and periodic limb movements of sleep: response and complications of extended treatment in 49 cases. Sleep 1993, 16:713-716.
356. Earley C.J., Yaffee J.B., Allen R.P. Randomized, double blind, placebo-controlled trial of pergolide in restless legs syndrome. Neurology 1998, 51:1599-1602.
357. Montplaisir J., Nicolas A., Denesle R., et al. Restless legs syndrome improved by pramipexole: a double blind randomized trial. Urology 1999, 52:938-943.
358. 3 receptor antagonists-preliminary results. Scand J Rheumatol 2000, 113:72-77.
359. Guymer E.K., Clauw D.J. Treatment of fatigue in fibromyalgia. Rheum Dis Clin North Am 2002, 28(2):367-378.
360. Martinez-Lavin M., Hermosillo A.G. Autonomic nervous system dysfunction may explain the multisystem features of fibromyalgia. Semin Arthritis Rheum 2000, 29:197-199.
361. Karas B., Grubb B.P., Boehm K., et al. The postural orthostatic tachycardia syndrome: a potentially treatable cause of chronic fatigue, exercise intolerance and cognitive impairment in adolescents. Pacing Clin Electrophysiol 2000, 23:344-351.
362. Raj S.R., Brouillard D., Simpson C.S., et al. Dysautonomia among patients with fibromyalgia: a non-invasive assessment. J Rheumatol 2000, 27:2660-2665.
363. Wilke W.S., Fouad-Tarazi, Cash J.M., et al. The connection between chronic fatigue syndrome and neurally mediated hypotension. Cleve Clin J Med 1998, 65:261-266.
364. Barkhuizen A. Rational and targeted pharmacologic treatment of fibromyalgia. Rheum Dis Clin North Am 2002, 28(2):261-290.
365. Bennett R.M., Clark S.R., Campbell S.M., et al. Symptoms of Raynaud's syndrome in patients with fibromyalgia. A study utilizing the Nielsen test, digital photoplethysmography and measurement of platelet alpha 2-adrenergic receptors. Arthritis Rheum 1991, 34:264-269.
366. Sletvold H., Stiles T.C., Landro N.I. Information processing in primary fibromyalgia, major depression and healthy controls. J Rheumatol 1995, 22:137-142.
367. Landro N.I., Stiles T.C., Sletvold H. Memory functioning in patients with primary fibromyalgia an major depression and healthy controls. J Psychosom Res 1997, 42:297-306.
368. Wahner-Roedler D.L., Elkin P.L., Vincent A., et al. Use of complementary and alternative medical therapies by patients referred to a fibromyalgia treatment program at a tertiary care center. Mayo Clin Proc 2005, 80(6):826.
369. Forseth K., Gran J.T. Management of fibromyalgia: what are the best treatment choices?. Drugs 2002, 6(4):577-592.
370. Hadhazy V.A., Ezzo J., Creamer P., et al. Mind-body therapies for the treatment of fibromyalgia. A systematic review. J Rheumatol 2000, 27(12):2911-2918.
371. Berman B.M., Swyers J.P. Complementary medicine treatments for fibromyalgia syndrome. Baillieres Best Pract Res Clin Rheumatol 1999, 13(3):487-492.
372. White K.P., Harth M. An analytical review of 24 controlled clinical trials for fibromyalgia syndrome (FMS). Pain 1996, 64(2):211-219.
373. Rossy L.A., Buckelew S.P., Dorr N., et al. A meta-analysis of fibromyalgia treatment interventions. Ann Behav Med 1999, 21:180-191.
374. Sim J., Adams N. Systematic review of randomized controlled trials of nonpharmacological interventions for fibromyalgia. Clin J Pain 2002, 18(5):324-336.
375. Rosen N.B. Physical medicine and rehabilitation approaches to the management of myofascial pain and fibromyalgia syndromes. Baillieres Clin Rheumatol 1994, 8(4):881-916.
376. Field T., Diego M., Cullen C., et al. Fibromyalgia pain and substance P decrease and sleep improves after massage therapy. J Clin Rheumatol 2002, 8(2):72-76.
377. Caballero-Uribe C.V., Abuchaibe I., Abuchaibe S., et al. Treatment of tender points in patients with fibromyalgia syndrome (FMS) with therapeutic infrared laser ray. Arthritis Rheum 1997, 40(9)(suppl):S44.
378. Kaada B. Treatment of fibromyalgia by low-frequency transcutaneous nerve stimulation. Tidsskr Nor Laegeforen 1989, 109(29):2992-2995.
379. Guieu R., Blin O., Pouget J., et al. Nociceptive threshold and physical activity. Can J Neurol Sci 1992, 19:69-71.
380. Koltyn K.F., Garvin A.W., Gardiner R.L., et al. Perception of pain following aerobic exercise. Med Sci Sports Exerc 1996, 28:1418-1421.
381. Schwarz L., Kindermann W. Changes in beta-endorphin levels in response to aerobic and anaerobic exercise. Sports Med 1992, 13:25-36.
382. Koltyn K.F. Analgesia following exercise: a review. Sports Med 2000, 29:85-98.
383. Geel S.E. The fibromyalgia syndrome: musculoskeletal pathophysiology. Semin Arthritis Rheum 1994, 23:347-353.
384. Watkins L.R., Maier S.F., Goehler L.E. Immune activation: the role of proinflammatory cytokines in inflammation, illness responses and pathological pain states. Pain 1995, 63:289-302.
385. Bennett R.M. The contribution of muscle to the generation of fibromyalgia symptomatology. J Musculoskelet Pain 1996, 4:35-59.
386. McCain G.A., Bell D.A., Mai F.M., et al. A controlled study of the effects of a supervised cardiovascular fitness training program on the manifestations of primary fibromyalgia. Arthritis Rheum 1988, 31:1135-1141.
387. Norregaard J., Lyddegaard J.J., Mehlsen J., et al. Exercise training in treatment of fibromyalgia. J Musculoskelet Pain 1997, 5:71-79.
388. Nichols D.S., Glenn T.M. Effects of aerobic exercise on pain perception, affect and level of disability in individuals with fibromyalgia. Phys Ther 1994, 74:327-332.
389. Martin L., Nutting A., Macintosh B.R., et al. An exercise program in the treatment of fibromyalgia. J Rheumatol 1996, 23:1050-1053.
390. Wigers S.H., Stiles T.C., Vogel P.A. Effects of aerobic exercise versus stress management treatment in fibromyalgia. A 4.5 year prospective study. Scand J Rheumatol 1996, 25:77-86.
391. Jones K.D., Burckhardt C.S., Clark S.R. A randomized controlled trial of muscle strengthening versus flexibility training in fibromyalgia. J Rheumatol 2002, 29:1041-1048.
392. Richards S.C., Scott D.L. Prescribed exercise in people with fibromyalgia: parallel group randomized controlled trial. Br Med J 2002, 325(7357):185.
393. Millea P.J., Holloway R.L. Treating fibromyalgia. Am Fam Physician 2000, 62:1575-1582.
394. Gowans S.E., Dehueck A., Voss S., et al. Six-month and one-year follow-up of 23 weeks of aerobic exercise for individuals with fibromyalgia. Arthritis Rheum 2004, 51(6):890-898.
395. Mannerkorpi K. Exercise in fibromyalgia. Curr Opin Rheumatol 2005, 17(2):190-194.
396. Da Costa D., Abrahamowicz M., Lowensteyn I., et al. A randomized clinical trial of an individualized home-based exercise programme for women with fibromyalgia. Rheumatology (Oxford) 2005, 44(11):1422-1427.
397. Maquet D., Croisier J.L., Demoulin C., et al. Value of aerobic rehabilitation in the management of fibromyalgia. Rev Med Liege 2006, 61(2):109-116.
398. Busch A., Schachter C.L., Peloso P.M., et al. Exercise for treating fibromyalgia syndrome. Cochrane Database Syst Rev 2002, 3. CD003786.
399. Gowans S.E., deHueck A., Voss S., et al. A randomized, controlled trial of exercise and education for individuals with fibromyalgia. Arthritis Care Res 1999, 12(2):120-128.
400. Ramsay C., Moreland J., Ho M., et al. An observer blinded comparison of supervised and unsupervised aerobic exercise regimen in fibromyalgia. Rheumatology 2000, 39(5):501-505.
401. Hauser W., Klose P., Langhorst J., et al. Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomized controlled studies. Arthritis Res Ther 2010, 12(3):R79.
402. Busch A.J., Barber K.A., Overend T.J., Peloso P.M., Schacter C.L. Exercise for treating fibromyalgia syndrome. Cochrane Database Sys Rev 2007.
403. Schneider M., Vernon H., Ko G., et al. Chiropractic management of fibromyalgia syndrome: a systematic review of the literature. J Manipulative Physiol Ther 2009, 32(1):25-40.
404. Berman B.M., Ezzo J., Hadhazy V., et al. Is acupuncture effective in the treatment of fibromyalgia?. J Fam Pract 1999, 48:213-218.
405. Sprott H., Franke S., Kluge H., et al. Pain treatment in fibromyalgia by acupuncture [letter]. Rheumatol Int 1998, 18(1):35-36.
406. Acupuncture. J Am Med Assoc 1998, 280:1518-1524. NIH Consensus Conference.
407. Singh B.B., Wu W.S., Hwang S.H., et al. Effectiveness of acupuncture in the treatment of fibromyalgia. Altern Ther Health Med 2006, 12(2):34-41.
408. Nielson W.R., Walker C., McCain G.A. Cognitive behavioral treatment of fibromyalgia syndrome: preliminary findings. J Rheumatol 1992, 19:98-103.
409. Vlaeyen J.W., Teeken-Gruben N.J., Goossens M.E., et al. Cognitive educational treatment of fibromyalgia: a randomized trial. I. Clinical effects. J Rheumatol 1996, 23:1237-1245.
410. Goldenberg D.L., Kaplan K.H., Nadeau M. A controlled study of a stress-reduction, cognitive-behavioral treatment program in fibromyalgia. J Musculoskelet Pain 1994, 2(2):53-66.
411. White K.P., Nielson W.R. Cognitive behavioral treatment of fibromyalgia syndrome: a follow-up assessment. J Rheumatol 1995, 22:717-721.
412. Keel P.J., Bodoky C., Gerhard U., Muller W. Comparison of integrated group therapy and group relaxation training for fibromyalgia. Clin J Pain 1998, 14(3):232-238.
413. Vazquez-Rivera S., Gonzalez-Blanch C., Rodriguez-Moya L., Moron D., Gonzalez-Vives S., Carrasco J.L. Brief cognitive-behavioral therapy with fibromyalgia patients in routine care. Compr Psychiatry 2009, 50(6):517-525. 374.
414. Turk D.C., Okifuji A., Sinclair J.D., et al. Interdisciplinary treatment for fibromyalgia syndrome: clinical and statistical significance. Arthritis Care Res 1998, 11:186-195.
415. Mengshoel A.M., Forseth K.O., Haugen M. Multidisciplinary approach to fibromyalgia. A pilot study. Clin Rheumatol 1995, 14:165-170.
416. Lami J.B., Martinez M.P., Sanchez A.I. Systematic review of psychological treatment in fibromyalgia. Curr Pain Headache Rep 2013, 17(7):345.
417. Glombiewsky J.A., Bernardy K., Hauser W. Efficacy of EMG- and EEG-biofeedback in fibromyalgia syndrome: a meta-analysis and a systematic review of randomized controlled trials. Evid Based Complement Altern Med 2013, 2013:962741.
418. Lemstra M., Olszynski W.P. The effectiveness of multidisciplinary rehabilitation in the treatment of fibromyalgia: a randomized controlled trial. Clin J Pain 2005, 21(2):166-174.
419. Luedtke C.A., Thompson J.M., Postier J.A., et al. A description of a brief multidisciplinary treatment program for fibromyalgia. Pain Manag Nurs 2005, 6(2):76-80.
420. Dobkin P.L., Ionescu-Ittu R., Abrahamowicz M., et al. Predictors of adherence to an integrated multimodal program for fibromyalgia. J Rheumatol 2008, 35(11):2255-2264.
421. Mant D. A case of mural dyslexia. Br J Gen Practice 2002, 52(480):579-583.
422. Bennett R.M. Multidisciplinary group programs to treat fibromyalgia patients. Rheum Dis Clin North Am 1996, 22(2):351-367.
423. Turk D.C., Okifuji A., Sinclair J.D., Starz T.W. Differential responses by psychosocial subgroups of fibromyalgia syndrome patients to an interdisciplinary treatment. Arthritis Care Res 1998, 11(5):397-404.
424. Lera S., Gelman S.M., Lopez M.J., et al. Multidisciplinary treatment of fibromyalgia: does cognitive behavior therapy increase the response to treatment?. J Psychosom Res 2009, 67(5):433-441.
425. Martin J., Torre F., Padierna A., et al. Six and 12-month follow-up of an interdisciplinary fibromyalgia treatment program: results of a randomised trial. Clin Exp Rheumatol 2012, 30(6 suppl 74):103-111.
426. Martin J., Torre F., Padierna A., et al. Interdisciplinary treatment of patients with fibromyalgia: improvement of their health-related quality of life. Pain Pract 2013, [epub ahead of print]. 10.1111/papr.12134.
427. Martin J., Torre F., Aguirre U., et al. Evaluation of the interdisciplinary PSYMEPHY treatment on patients with fibromyalgia: a randomized control trial. Pain Med 2014, 15(4):682-691.
428. Interdisciplinary fibromyalgia treatment benefits sustained. Medscape.com. Mar 14, 2014.
429. Facts and Comparisons.com.
430. Lexi-Comp Online-Lexicomp Online Login.
431. Barkin R.L., Barkin S. The role of venlafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical considerations of duloxetine pharmacotherapy. Am J Ther 2005, 12(5):431-4388.
432. Leo R.J., Barkin R.L. Antidepressant use in chronic pain management: is there evidence of a role for duloxetine?. Prim Care Companion J Clin Psychiatry 2003, 5(3):118-123.
433. Bradley R.H., Barkin R.L., Jerome J., et al. Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder. Am J Ther 2003, 10(5):318-323.
434. Smith H.S., Barkin R.L. Fibromyalgia syndrome: a discussion of the syndrome and pharmacotherapy (review). Am J Ther 2010, 17(4):418-439.
435. Smith H.S., Barkin R.L. Fibromyalgia syndrome: a discussion of the syndrome and pharmacotherapy. Am J Ther 2011, 57(4):248-285.
436. Barkin R.L., Chor P.N., Braun B.G., Schwer W.A. A trilogy case review highlighting the clinical and pharmacologic applications of mirtazapine in reducing polypharmacy for anxiety, agitation, insomnia, depression, and sexual dysfunction. Prim Care Companion J Clin Psychiatry 1999, 1(5):142-145.
437. Beebe F.A., Barkin R.L., Barkin S. A clinical and pharmacologic review of skeletal muscle relaxants for musculoskeletal conditions. Am J Ther 2005, 12(2):151-171.
438. Jay G.W., Barkin R.L. Neuropathic pain: etiology, pathophysiology, mechanisms, and evaluations. Dis Mon 2014, 60(1):6-47.
439. Bruckenthal P., Barkin R.L. Options for treating postherpetic neuralgia in the medically complicated patient. Ther Clin Risk Manag 2013, 9:329-340.
440. Smith H.S., Barkin R.L., Barkin S. Personalized pharmacotherapy for treatment approaches focused at primary insomnia. Am J Ther 2011, 18(3):227-240.
441. Novakovic V., Barkin R.L., Hamner M.B., LeClear O'Connell K. Schizophrenia: improving the continuity of care to ensure optimal patient outcomes. Dis Mon 2012, 58(7):395-409.
442. Barkin R.L. Zolpidem extended-release: a single insomnia treatment option for sleep induction and sleep maintenance symptoms. Am J Ther 2007, 14(3):299-305.
443. Huff J.P., Barkin R.L., Lagattuta F.P. A primary care clinician's and consultant's guide to medicating for pain and anxiety associated with outpatient procedures. Am J Ther 1994, 1(3):186-190.
444. Barkin R.L., Barkin S. The epidemiology and diagnosis of schizophrenia and the therapeutic options, communication, and collaborative case plan. Dis Mon 2012, 58(7):394.
445. Barkin R.L. Interview: the need to tailor pain management approaches to individual requirements. Pain Manag 2012, 2(5):435-436.